Revenue from operations jumped 10.33% year on year to Rs 2,308.85 crore in the quarter ended 30 June 2025.
Profit before tax (PBT) increased 13.81% to Rs 330.51 crore in Q1 FY25, compared with Rs 290.39 crore in Q1 FY25.
EBITDA stood at Rs 424.58 crore in Q1 FY26, registering the growth of 10%, compared with Rs 387.49 crore in Q1 FY25. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) stood at 18.39% in Q1 FY26 as against at 18.52% in Q1 FY25.
During the quarter, total formulations were at Rs 1,410.62 crore, up 11% YoY. Domestic business stood at Rs 961.01 crore (up 10% YoY).
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.
Shares of Ipca Laboratories fell 3.62% to Rs 1,334.40 on the BSE.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."